drugset
drugset / Trial / NCT00001992

A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

NCT00001992 ↗

Phase 1 Completed Genentech, Inc.
Prevention

Summary

To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject rgp120/HIV-1IIIB Vaccine — —

Indications

HIV infectious disease